Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Feb 14, 2008 1:50pm
101 Views
Post# 14374089

RE: Interesting Alzheimer research

RE: Interesting Alzheimer research That is pretty spacey W7.......but even more interesting is the work being done with the Amyloid Cascade. It keeps getting more and more clear with every study. The Fact that AZD-103 REVERSES Synaptic Failure due to soluble Oligomers is mind blowing. Shankar says....."Alzheimer’s disease (AD) is characterized by decreased synapse density in hippocampus and neocortex, and synapse loss is the strongest anatomical correlate of the degree of clinical impairment. Although considerable evidence supports a causal role for the amyloid-beta protein (Ab) in AD, a direct link between a specific form of Ab and synapse loss has not been established. We demonstrate that physiological concentrations of naturally secreted Ab dimers and trimers, but not monomers, induce progressive loss of hippocampal synapses. Pyramidal neurons in rat organotypic slices had markedly decreased density of dendritic spines and numbers of electrophysiologically active synapses after exposure to picomolar levels of soluble oligomers. Spine loss was REVERSIBLE and was prevented by Ab-specific antibodies (think Elans aab001) or a small-molecule modulator of Ab aggregation (think AZD-103/ELND005). Mechanistically, Ab-mediated spine loss required activity of NMDA-type glutamate receptors (NMDARs) and occurred through a pathway involving cofilin and calcineurin. Furthermore, NMDAR mediated calcium influx into active spines was reduced by Ab oligomers. Partial blockade of NMDARs by pharmacological antagonists was sufficient to trigger spine loss." "We conclude that soluble, low-n oligomers of human Ab trigger synapse loss that can be reversed by therapeutic agents (AZD-103). Our approach provides a quantitative cellular model for elucidating the molecular basis of Ab-induced neuronal dysfunction." Now THATS amazingly compelling.........They showed that the Brains Neurons FAIL from the oligomerized Ab. They have electrophysiological evidence repeated 1000 TIMES with the same result....each and every time......AZD-103 REVERSES the effects. IMO the helmet does look COOL............LOL!! .
Bullboard Posts